WEST PHARMACEUTICAL SERVICES INC (WST) Form 8-K — Jun 1, 2026
West Pharmaceutical Services (WST) has appointed Michel Lagarde as its new President and Chief Executive Officer, effective August 31, 2026, succeeding Eric M. Green who is retiring after leading the company for many years. Lagarde, currently Executive Vice President and COO at Thermo Fisher Scientific, brings extensive experience in the life sciences sector, having previously led Patheon N.V. and served on the board of Vertex Pharmaceuticals.
Key figures
- Base Salary
- 1175000
- Target Bonus
- 1468750
- Lti Grant Value
- 8611111
- Matching Grant Cap
- 2500000
- Sign On Grant Value
- 6875000
- Total Equity Value
- 18000000
- Lti Mix
- 50% PSUs, 25% RSUs, 25% Stock Options
- Start Date
- 2026-08-31
- Vesting Period
- 5 years for matching grants
- Matching Grant Terms
- 50% RSUs, 75% Stock Options of purchase amount
Price after filing
1 day: -1.3%7 days: +1.1%30 days: +13.5%
Close on the filing date to close N calendar days later (from $316.30). Historical, not a forecast.
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.